Promoter hypomethylation is associated with increased expression of AXL in HER2 inhibitor-resistant breast cancers [35], acute myeloid leukemia (AML) [36], and some colorectal models [17]. This evidence concerns the gene ERBB2 and acute myeloid leukemia.